Antibody Engineering Xchange West Coast 2018

Antibody Engineering

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

How to identify the best antibody discovery platforms to move forward with for lead identification

Which platforms are you using for active discovery projects?
What are the main strengths and weaknesses of these platforms?
What are the primary factors that influence your platform choices? (scientific, operational, IP/technology access)
Does/should desired antibody function (e.g. receptor agonism, ligand blocking) influence discovery platform choice?
Are you evaluating (or planning to evaluate) any new platform technology? What and why?

Shelley Force Aldred

Vice President Preclinical
Development,
TeneoBio

10:30am – 11:30am

Maximizing target-specific antibody sequence diversity in discovery campaigns

Considerations for immunization strategies (species, strains, and routes)
Perceived advantages and disadvantages of discovery platforms
Screening assay formats: Binders and functioners.

Barry Duplantis

CRPM
ImmunoPrecise Antibodies

12:00pm – 1:00pm

How to identify the best agonistic antibody for trimeric receptors such as TNF receptors for immuno-oncology

What are the considerations in selecting an agonistic antibody against TNFR?
What is the best format for agonistic antibodies targeting a TNFR, bivalent or trivalent?
Do you prefer partial, full, or super agonistic antibodies?
Is crosslinking two TNFRs or super-agonistic antibody preferred?
What kind of functional cell-based assays are predictable for in vivo efficacy?
What in vivo models can predict efficacy in clinic trials?

David Shen

Senior Vice President
Head of Biologics Research
& CMC, NGM
Biopharmaceuticals

3:20pm – 4:20pm

Selection of antibodies specific for multi-pass membrane proteins using mammalian virus display

What are the biggest challenges to overcome to enable selection of antibodies specific for multi-pass membrane proteins?
What are the available technical solutions to these challenges?
How can recombinant virus display and VLPs be used to overcome these challenges?

Ernest Smith

Ernest Smith
Senior Vice President Research &
Chief Scientific Officer
Vaccinex

4:20pm – 5:20pm

Interrogating the human immune system for antibody discovery.

What’s the best tissue source (blood, tumor, lymphoid tissue) to interrogate humoral response to cancer?
Should interrogation of humoral system be target-driven, target-agnostic or both?
Should screening assays focus on discovery of a single therapeutic antibody or a combination of multiple antibodies?
What are current challenges in screening assays to identify therapeutic antibodies?
What approaches are best suited to identify target for novel antibodies?

Kamal Puri

Vice President R&D
OncoResponse

Antibody Engineering

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Antibody optimization strategies balancing antigen affinity, functional activity, and manufacturing developability

What is the therapeutic targeting strategy?
What key attributes define a well-designed antibody?
What strategies and platforms are found to be most effective for lead optimization?

Scott Glaser

Director
Antibody Therapeutics

10:30am – 11:30am

Antibody Discovery Topic: How to effectively use Rabbit monoclonal antibodies for therapeutic antibody discovery?

Rabbit monoclonal antibodies as an antibody tool for therapeutic antibody discovery
What are the unique advantages of B cell cloning technology?
Building the rabbit B-cell antibody library by Next-Generation sequencing technology.

Li Hui

Senior Principal Scientist
ABclonal

3:20pm – 4:20pm

A balanced approach to developability analysis throughout antibody discovery.

How early do we begin our developability assessments during the drug discovery process?
How do we prioritise antibody attributes at each stage of the process?
Which analytical approaches are most valuable in initial developability assessments?

Jody Haddow

Business Development –North America
Fusion Antibodies

4:20pm – 5:20pm

“*Antibody Engineering Topic*: Strategies to manage immunogenicity risk and test functionality during early development”.

Tools for early immunogenicity assessment (in silico, in vitro, MAPPS,..) how and when to use them?
Predictive immunogenicity facts and myths
The use of human primary cells for functional testing of IO drugs, benefits and limitations

Sofie Pattijn

Founder & Chief Technology Officer
ImmunXperts

Bispecific Antibodies

Time

Titles and Bullets

Facilitator

10:30am – 11:30am

Will bispecific antibodies dethrone monotherapy for treating cancer?

Is redirecting T-cells with bispecific antibodies safer than CAR-T cell therapy?
Is the complexity of bispecific antibodies hindering their development over conventional antibodies?
Beyond CD3 bispecifics, what is the future for discovering new targets as we understand more about tumor biology?

Yasmina Abdiche

Chief Scientific Officer
Carterra

12:00pm – 1:00pm

Bispecific antibody-mediated T-cell redirection

CD3 based platforms
Emerging T-cell targets
Solid tumor targets
Safety

Nathan Trinklein

Vice President
TeneoBio

3:20pm – 4:20pm

Antibody Discovery Topic: How to apply NGS technology to speedup Ab lead discovery and increase lead Ab sequence diversity

What are the strengths, limitations, and best practices for using NGS for antibody discovery and engineering?
How can NGS be used to characterize the natural immune repertoire and discover drug hits?
How can NGS aide the design and evaluation of antibody libraries?
How can NGS data be integrated into an antibody engineering knowledge-base?

Natalie Castellana

Chief Executive Officer
Digital Proteomics

4:20pm – 5:20pm

Developing a plug-and-play platform approach for bispecific generation and development

What is the need for plug-and-play platforms to generate bi-specific generation? [discuss the need, advantages, and risks of using such platforms].
At what level would these plug-and-platforms be most useful: Research only vs R&D? [research level advantages vs clinical risks like immunogenicity].
Chemical conjugation mediated modalities for bi-specific generation.
Protein-ligation based modalities for bi-specific generation.

Madan Paidhungat

Head of Protein Engineering
Cytomx

Antibody Drug Conjugates

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Translating ADCs from preclinical into clinical

How can we use data from the clinical studies to improve the preclinical development of ADCs?
How has ADC technology improved and what are the shortcomings?
Will improvements in the preclinical development of ADCs improve the clinical success rates for ADCs?

Dowdy Jackson

Managing Director
Jackson Consulting Group

10:30am – 11:30am

Addressing the complexity of bringing an ADC from early stage to BLA and managing the criticalities for DS & DP manufacturing

When and how the manufacturing process characterization for DS and DP should be planned?
Which complexities and benefits do you typically face if you look for an Integrated system to manage the manufacture of DS and DP
How can you define the proper strategy for a successful scale up that could also fulfill the regulatory requirements?
How do you prepare for a fast growing demand of capacity and increased complexity of the process when your product is granted with an accelerated approval pathway?

Giorgio Salciarini

Technical Business Development Manager
BSP
Pharmaceuticals

12:00pm – 1:00pm

Developing a novel high-throughput screening approach to optimise the selection of an antibody for a specific target, tumour, linker and drug for ADC development.

What can be done to improve tumor uptake?
What can be done to facilitate tumor penetration?
What key efficacy model parameters could be explored
differently to improve the clinical translation?

Anthony Haight

Senior Research Fellow Director
Development Sciences
Abbvie

Cancer Immunotherapies

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Using multispecific antibodies to design molecules to fine-tune T cell function to kill tumour cells

What do we know so far about the various multispecific constructs and the impact on the cytotoxic activity of T-cell engagers?
Do smaller non IgG constructs have an advantage over the IgG platform?
Is there enough data to support that a short serum half-life molecule has better tolerability and is a better approach for T-cell engagers over long half-life molecules?
How much do we know about tumor penetration with multispecific constructs?

Seema Kantak

Executive Director
Biotherapeutics
Exelixis

12:00pm – 1:00pm

How to decide the choice of Fc engineering for multispecifics for immuno-oncology.

Choosing among the standard isotypes: G1, G2, G4…and now IgM.
Is effector function beneficial, detrimental or neutral: it depends – Effector function is multifaceted. Which are the right subsets of effector cells and receptors to drive the biology of your molecule? – Interaction with FcRs does more than trigger ADCC, it can drive vaccinal effects and lead to T cell memory.
Engineering half-life for optimal pharmacokinetics

Jonah Rainey

Chief Executive Officer
Oriole Biotech

3:20pm – 4:20pm

Antibody Discovery Topic: Improving efficiency in identifying lead candidates

The chicken or the egg: Functional screening vs. antibody sequencing
Assessing developability
Timeline & cost consideration
Optimal size of sequencing pool

Andra Li

Director of Molecular Laboratory Services
ImmunoPrecise Antibodies

4:20pm – 5:20pm

Developing antibodies to overcome challenges of target selection.

Soluble targets, how to select targets such as TNF or VEGF?
Cell surface receptors, how to design antibodies against pathway inhibitors such as Her2 or EGFr?
Cell receptors, how to choose targets in the checkpoint pathway, beyond PD-1 and PD-L1?
Antibody drug conjugates, what problems remain in developing ADC targeted antibodies?
Bispecific antibodies, what are the next generation bispecific mAbs after CD19xCD3?

Bruce Keyt

Chief Scientific Officer
IGM Biosciences

Antibody Engineering Xchange West Coast 2018

Antibody Engineering

Partners